RayzeBio Valuation

Is RYZB undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

1/6

Valuation Score 1/6

Below Fair Value
Significantly Below Fair Value
Price-To-Book vs Peers
Price-To-Book vs Industry
Price-To-Book vs Fair Ratio
Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of RYZB when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: Insufficient data to calculate RYZB's fair value for valuation analysis.

Significantly Below Fair Value: Insufficient data to calculate RYZB's fair value for valuation analysis.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for RYZB?

Key metric: As RYZB is unprofitable and pre-revenue we use its Price-To-Book Ratio for relative valuation analysis.

The above table shows the Price to Book ratio for RYZB. This is calculated by dividing RYZB's market cap by their current book value.
What is RYZB's PB Ratio?
PB Ratio	6.5x
Book	US$575.32m
Market Cap	US$3.74b

RYZB key valuation metrics and ratios. From Price to Earnings, Price to Sales and Price to Book to Price to Earnings Growth Ratio, Enterprise Value and EBITDA.
Key Statistics
Enterprise Value/Revenue	n/a
Enterprise Value/EBITDA	-43.5x
PEG Ratio	n/a

Price to Book Ratio vs Peers

How does RYZB's PB Ratio compare to its peers?

The above table shows the PB ratio for RYZB vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
Company	Forward PB	Estimated Growth	Market Cap
Peer Average	86x
TPTX Turning Point Therapeutics	4.8x	24.7%	US$3.8b
RYTM Rhythm Pharmaceuticals	328.5x	66.7%	US$3.7b
IMVT Immunovant	8.8x	8.3%	US$3.9b
CRSP CRISPR Therapeutics	2.1x	34.5%	US$4.1b
RYZB RayzeBio	6.5x	2.0%	US$3.7b

Price-To-Book vs Peers: RYZB is good value based on its Price-To-Book Ratio (6.5x) compared to the peer average (9.9x).

Price to Book Ratio vs Industry

How does RYZB's PB Ratio compare vs other companies in the US Biotechs Industry?

61 Companies	Price / Book	Estimated Growth	Market Cap
GRAL GRAIL	0.2x	35.7%	US$554.58m
IMAB I-Mab	0.4x	1.8%	US$76.59m
ACET Adicet Bio	0.4x	6.7%	US$74.16m
MGX Metagenomi	0.3x	-23.2%	US$70.73m

61 Companies		Estimated Growth	Market Cap

No more companies

Price-To-Book vs Industry: RYZB is expensive based on its Price-To-Book Ratio (6.5x) compared to the US Biotechs industry average (2.2x).

Price to Book Ratio vs Fair Ratio

What is RYZB's PB Ratio compared to its Fair PB Ratio? This is the expected PB Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

RYZB PB Ratio vs Fair Ratio.
Fair Ratio
Current PB Ratio	6.5x
Fair PB Ratio	n/a

Price-To-Book vs Fair Ratio: Insufficient data to calculate RYZB's Price-To-Book Fair Ratio for valuation analysis.

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

The above table shows the analyst RYZB forecast and predictions for the stock price in 12 month’s time.
Date	Share Price	Average 1Y Price Target	Dispersion	High	Low	1Y Actual price	Analysts
Current	n/a	US$53.33 0%	24.3%	US$62.50	US$35.00	n/a	3
Nov ’25	n/a	US$53.33 0%	24.3%	US$62.50	US$35.00	n/a	3
Oct ’25	n/a	US$53.33 0%	24.3%	US$62.50	US$35.00	n/a	3
Sep ’25	n/a	US$53.33 0%	24.3%	US$62.50	US$35.00	n/a	3
Aug ’25	n/a	US$53.33 0%	24.3%	US$62.50	US$35.00	n/a	3
Jul ’25	n/a	US$53.33 0%	24.3%	US$62.50	US$35.00	n/a	3
Jun ’25	n/a	US$53.33 0%	24.3%	US$62.50	US$35.00	n/a	3
May ’25	n/a	US$53.33 0%	24.3%	US$62.50	US$35.00	n/a	3
Apr ’25	n/a	US$53.33 0%	24.3%	US$62.50	US$35.00	n/a	3
Mar ’25	US$62.49	US$53.33 -14.7%	24.3%	US$62.50	US$35.00	n/a	3
Feb ’25	US$62.13	US$47.45 -23.6%	32.0%	US$62.50	US$29.79	n/a	4
Jan ’25	US$62.17	US$47.45 -23.7%	32.0%	US$62.50	US$29.79	n/a	4
Dec ’24	US$23.89	US$30.95 +29.5%	7.7%	US$35.00	US$29.00	n/a	4
Nov ’24	US$20.14	US$30.95 +53.7%	7.7%	US$35.00	US$29.00	n/a	4

Analyst Forecast: Target price is lower than the current share price.

Discover undervalued companies

Spectrum Pharmaceuticals

US$209.9m

Spectrum Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes oncology drug products.

SPPI

US$1.03

5.3%

17.0%

IQVIA Holdings

US$36.6b

Engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific.

IQV

US$201.82

4.7%

-4.8%

Collegium Pharmaceutical

US$966.2m

A specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management.

COLL

US$29.96

1.3%

15.1%